https://www.selleckchem.com/pr....oducts/Ispinesib-mes
Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins with twice-yearly dosing. The purpose of this study was to conduct a patient-level pooled analysis from 3 phase 3 studies of inclisiran. Participants with heterozygous familial hypercholesterolemia (ORION-9 [Trial to Evaluate the Effect of Inclisiran Treat
Like
Comment
Share
